Lexaria Bioscience

Lexaria Bioscience Revenue per Share

The Revenue per Share of Lexaria Bioscience (LEXX) as of Nov 19, 2026 is 0.50 USD. In the previous year, Revenue per Share was 0.42 USD — a change of 18.56% (higher).

Revenue per Share

0.50USD

YoY

18.56%

Last updated:

Revenue per Share of Lexaria Bioscience is 2025 0.50 USD. Revenue per Share of Lexaria Bioscience was 2024 0.42 USD. It decreases by 18.56% higher compared to the previous year.

The Lexaria Bioscience Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2024
0.42 USD
Jan 1, 2025
0.50 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.06 USD
Jan 1, 2028 (e)
0.06 USD
Jan 1, 2029 (e)
2.82 USD
Jan 1, 2030 (e)
5.58 USD
Jan 1, 2031 (e)
7.40 USD
The Lexaria Bioscience Revenue per Share history
YEARRevenue per ShareYoY
est7.40USD+32.56%
est5.58USD+98.03%
est2.82USD+4,328.14%
est0.06USD+12.97%
est0.06USD+6,915.00%
est0.00USD-99.84%
0.50USD+18.56%
0.42USD+11.45%
0.37USD-41.77%
0.64USD-65.99%
1.89USD-1.50%
1.92USD+51.77%
1.27USD-50.49%
2.56USD+512.93%
0.42USD+17.76%
0.35USD+135.01%
0.15USD-99.22%
19.22USD-29.60%
27.30USD0.00%
27.30USD-29.83%
38.90USD+7.75%
36.11USD+56.39%
23.09USD-20.12%
28.90USD-57.01%
67.22USD+184.14%
23.66USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lexaria Bioscience Stock analysis

What does Lexaria Bioscience do? Lexaria Bioscience Corp. generates revenue through its DehydraTECH drug delivery technology, which enhances the bioavailability of active pharmaceutical ingredients. The company operates in two segments: Intellectual Property and Products, licensing its patented technology to partners in the pharmaceutical industry. DehydraTECH formulations improve oral absorption and have demonstrated enhanced delivery into brain tissue, supporting applications for intraoral and topical administration. The firm holds 35 granted patents and numerous pending patents worldwide, leveraging its intellectual property portfolio for licensing agreements. The company's primary customers are pharmaceutical firms seeking to improve drug delivery for oral, intraoral, and topical formulations. These partners utilize DehydraTECH to increase the effectiveness of active molecules, particularly for applications requiring higher bioavailability or targeted brain delivery. Lexaria's technology is positioned to support the development of new pharmaceutical products without direct manufacturing involvement. Lexaria's business model relies on licensing its patented DehydraTECH technology to pharmaceutical companies, generating income through intellectual property agreements. The company does not produce or sell finished pharmaceutical products but instead focuses on technology licensing and intellectual property management. Its subsidiary Lexa is part of the corporate structure but does not drive revenue generation. Lexaria Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lexaria Bioscience stock

Revenue per Share of Lexaria Bioscience is 0.50 USD in 2025.

Revenue per Share of Lexaria Bioscience changed from 0.42 USD to 0.50 USD, representing a 18.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Lexaria Bioscience since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lexaria Bioscience

All Key Metrics — Lexaria Bioscience